News | October 29, 2025
Novartis completes acquisition of Tourmaline Bio
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline is now an indirect wholly owned subsidiary of Novartis
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Subscribe To Our Newsletter & Stay Updated
